SCHEMBL4408472

SCHEMBL4408472

Cn1c(C(C)(C)O)cc2nc(-c3ccc(F)cc3)c(-c3ccncc3)c(-c3ccc(F)cc3)c21

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 16/20 0.48
MAPK10 P53779 1/20 0.45
MAPK13 O15264 3/20 0.43
MAPK12 P53778 3/20 0.43
MAPK11 Q15759 3/20 0.43
CSNK1D P48730 2/20 0.41
CSNK1E P49674 2/20 0.41
CSNK1A1 P48729 1/20 0.41
BRAF P15056 3/20 0.41
SRC P12931 2/20 0.40
KDR P35968 2/20 0.40
EGFR P00533 1/20 0.40
RAF1 P04049 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
ADORA2A P29274 1/20 0.40
ADORA2B P29275 1/20 0.40
ADORA1 P30542 1/20 0.40
GSK3B P49841 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4412139 0.81 MAPK14 (0.48) MAPK14MAPK10MAPK13MAPK12MAPK11
SCHEMBL4408115 0.80 MAPK14 (0.47) MAPK14MAPK10MAPK13MAPK12MAPK11
SCHEMBL4410172 0.80 MAPK14 (0.47) MAPK14MAPK10MAPK13MAPK12MAPK11
SCHEMBL4410204 0.79 MAPK14 (0.46) MAPK14MAPK10MAPK13MAPK12MAPK11
SCHEMBL4409918 0.79 MAPK14 (0.48) MAPK14MAPK10MAPK13MAPK12MAPK11
SCHEMBL4415373 0.79 MAPK14 (0.44) MAPK14MAPK13MAPK12MAPK11CSNK1D
SCHEMBL4409114 0.77 HTR3A (0.47) MAPK14MAPK10MAPK13MAPK12MAPK11
SCHEMBL4406497 0.75 MAPK14 (0.51) MAPK14MAPK10MAPK13MAPK12MAPK11
SCHEMBL5497318 0.74 MAPK14 (0.43) MAPK14MAPK10MAPK13MAPK12MAPK11
SCHEMBL4408106 0.74 MAPK14 (0.44) MAPK14MAPK10MAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2009-10-22 US claimed
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2008-12-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors MAPK1, MAP4K2, MAP3K1 MAPK14 36/4885MAPK10 34/4885MAPK13 39/4885
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors MAPK1, MAP4K2, MAP3K1 MAPK14 36/4885MAPK10 34/4885MAPK13 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.